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Abstract
Background: Mesenchymal Stem Cells (MSCs) are a promising therapeutic tool in veterinary medicine. Currently
the subcutaneous adipose tissue is the leading source of MSCs in dogs. MSCs derived from distinct fat depots have
shown dissimilarities in their accessibility and therapeutic potential. The aims of our work were to determine the
suitability of omental adipose tissue as a source of MSCs, according to sampling success, cell yield and paracrine
properties of isolated cells, and compared to subcutaneous adipose tissue.
Results: While sampling success of omental adipose tissue was 100% (14 collections from14 donors) for
subcutaneous adipose tissue it was 71% (10 collections from 14 donors). MSCs could be isolated from both sources.
Cell yield was significantly higher for omental than for subcutaneous adipose tissue (38 ± 1 vs. 30 ± 1 CFU-F/g
tissue, p < 0.0001). No differences were observed between sources regarding cell proliferation potential (73 ± 1 vs.
74 ± 1 CDPL) and cell senescence (at passage 10, both cultures presented enlarged cells with cytoplasmic vacuoles
and cellular debris). Omental- and subcutaneous-derived MSCs expressed at the same level bFGF, PDGF, HGF, VEGF,
ANG1 and IL-10. Irrespective of the source, isolated MSCs induced proliferation, migration and vascularization of
target cells, and inhibited the activation of T lymphocytes.
Conclusion: Compared to subcutaneous adipose tissue, omental adipose tissue is a more suitable source of MSCs
in dogs. Since it can be procured from donors with any body condition, its collection procedure is always feasible,
its cell yield is high and the MSCs isolated from it have desirable differentiation and paracrine potentials.
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Background
Mesenchymal stem cells (MSCs) are non-hematopoietic
precursor cells that can be differentiated, among others,
into chondrocytes, osteocytes and adipocytes [1]. To-
gether, MSCs secrete trophic, vasculogenic and immuno-
modulatory factors that have a paracrine effect on tissue
resident cells [2–4]. Hence, MSCs are a promissory
therapeutic tool for regenerative medicine [5].
The leading source of MSCs is the bone marrow. In
2001, they were isolated for the first time from adi-
pose tissue [6]. When compared to bone marrow, adi-
pose tissue appeared as a superior source of MSCs
due to the fact that a less invasive procedure is re-
quired to procure it [7–9].
In veterinary medicine, it has been proven that the
administration of adipose-derived MSCs have thera-
peutic effects in small animal patients, particularly in
cats and dogs [10–13]. Adult dogs have adipose tissue
locates mainly in subcutaneous and visceral depots.
Thus, adipose tissue may be procured through min-
imally invasive procedures from arms, thighs and ab-
domen (subcutaneous), or from omentum, kidney and
liver (visceral) [14, 15]. While the abundance of sub-
cutaneous adipose tissue depends on the body condition,
the extent of omentum is relatively constant [16, 17]. It
has been demonstrated that there are MSCs in the omen-
tum of both dogs [10, 18] and humans [19, 20]. Omental-
derived MSCs are similar to subcutaneous-derived MSCs
according to their proliferation and surface antigen ex-
pression [18]. Up to our knowledge, no data are available
regarding the abundance and paracrine potential of
omental-derived MSCs. Since previous studies showed
that adipose-derived MSC properties vary from depot to
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depot [21], it will be also interesting to compare MSCs
isolated form omentum with those isolated from subcuta-
neous fat, the leading adipose source of MSCs.
The aims of our work were to determine the suitability
of omental adipose tissue as a source of MSCs, accord-
ing to sampling success, cell yield and paracrine proper-
ties of isolated cells, and compared to subcutaneous
adipose tissue.
Methods
Collection of adipose tissue
Fourteen female dogs of different breeds, 6–12 months
old, with normal corporal condition, clinically healthy
and having elective ovariohysterectomies were enrolled
in the study, after client-owned provided written in-
formed consent. Animals were pre-anesthetized with
0.04 mg/Kg Acepromazine (Holliday-Scott S.A, Buenos
Aires, Argentina). General anesthesia was induced with
3 mg/Kg Propofol (Fresenius Kabi, Spain) and main-
tained with Isofluorane (Baxter Healthcare Corporation,
Deerfield, IL). Approximately 3cm3 (5-10 g) of omental
and subcutaneous adipose tissue were procured from
greater omentum and abdominal region, respectively.
Subsequently, an ovariohysterectomy was performed.
Muscular and skin incisions were sutured with a sim-
ple, interrupted pattern. Up to three days post-surgery
animals received 1 mg/Kg/24 h Ketoprofen (Merial
Laboratorios, Argentina).
Study was approved by Ethic Committee Facultad de
Ciencias Veterinarias y Pecuarias, Universidad de Chile
(No. 03–2014).
Isolation, ex vivo expansion and characterization of MSCs
Adipose tissue samples were weighed, washed with
phosphate buffered saline (PBS. Sigma, St. Louis, MO,
USA) containing 80 μg/mL gentamycin (Sanderson
Laboratory, Santiago, Chile), minced with scissors and
scalpels, and digested in PBS containing 1 mg/mL colla-
genase type II (Gibco, Grand Island, NY, USA), at 37 °C,
overnight. Enzyme activity was neutralized with alpha-
MEM (Gibco, Auckland, NZ) supplemented with 10%
fetal bovine serum (Gibco, Auckland, NZ) and 80 μg/mL
gentamicin (Sanderson Laboratory, Santiago, Chile)
(here after expansion medium), and centrifuged at
400×g for 10 min. Pelleted cells were resuspended in ex-
pansion medium and plated at a density of 50,000 nucle-
ated cells/cm2 and cultured under an atmosphere with
5% CO2, at 37 °C. Fourty eight hours later, nonadherent
cells were removed by media change. When 80% conflu-
ence was achieved, adherent cells were detached with
0.25% trypsin and 2.65 mM EDTA, centrifuged and sub-
cultured at 5000 cells/cm2. After two subcultures, adher-
ent cells were characterized according to their
adipogenic [21], chondrogenic [22] and osteogenic
differentiation potential [23]. Although there are cur-
rently no consensus markers for canine MSCs as there
are for human MSCs [1], immunophenotyping was per-
formed by flow cytometry analysis after labeling with
monoclonal antibodies against: CD45FITC, CD11bPE-Cy5,
CD44APC and CD90PE or their respective isotype con-
trols (rat IgG2bFITC, rat IgG2bPE-Cy5, rat IgG2bAPC or rat
IgG2bPE; eBioscience, San Diego, CA).
Fibroblast-like Colony forming unit (CFU-F) assay
CFU-F assay was performed on freshly isolated cells as
previously described [24]. Briefly, 500 mononuclear
cells/cm2 were cultured in expansion medium. At day 7,
cells were fixed with 4% paraformaldehyde for 10 min
and stained with 0.5% crystal violet (Sigma-Aldrich, St.
Louis, MO) in 10% methanol for 20 min. Plates were ob-
served under light microscope (Leica DM2000). Clusters
containing more than 50 cells were scored as CFU-Fs
and counted. Results were expressed as CFU-F per gram
of tissue (CFU-F/g tissue).
Assays were performed in triplicate.
Evaluation of cumulative population doubling level
(CPDL) and senescence
One thousand cells/cm2 were seeded and cultured with
expansion medium. The medium was changed every
three days and cells were subcultured when reaching
80% confluence. The population doubling (PD) at each
subculture was calculated according to the formula
PD = ln (Nf/Ni) /ln 2, where Ni and Nf are initial and
final cell numbers, respectively. The PDs of continuous
subcultures were added to obtain CPDL [10].
Senescence was assessed looking for changes in cell
morphology such as cell enlargement, accumulation of
vacuoles and presence of cellular debris [25].
Assays were performed in triplicate.
RT-qPCR
RNA was extracted from cells using Tryzol (Invitrogen,
Carlsbad, CA, USA) and treated with DNAse (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s in-
structions. One μg of RNA was reverse-transcribed using
oligo-dT primers and Moloney murine leukemia virus
reverse transcriptase. The abundance of mRNA was de-
termined by qPCR using SYBR Green Technology and
canine-specific primers for bFGF, PDGF HGF, VEGF,
ANG1, IDO, IL-10 and 18S (Additional file 1: Table S1).
Cycling condition were: 1 cycle, 94 °C for 10 min; 30–
35 cycles, 94 °C for 10 min; optimal annealing
temperature for 5 min; 72 °C for 4 min; 1 cycle, 64 °C
for 10 min; 1 cycle, 40 °C for 30 min. The qPCR prod-
ucts were separated by electrophoresis on 2% agarose
gel, stained with 1% ethidium bromide and visualized
under UV light. Digital images were captured with
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Alpha imagen software. Values were normalized to 18S
mRNA levels. Relative gene expression was quantified
with the 2 -ΔΔCt method [26].
Proliferation assay
Human fibroblasts were seeded at 4000 cells/cm2 and
cultivated with alpha-MEM (control) or alpha-MEM
conditioned by MSCs for 24 h. The medium was chan-
ged every 3 days. Three, six, nine and 12 days later, cells
were stained with 0.5% crystal violet in 10% methanol
for 20 min. After four washes, crystal violet incorporated
into the cells were solubilized with 50% methanol in PBS
and quantified spectrophotometrically (absorbance at
570 nm) [24].
Assays were performed in triplicate.
Scratch assay
Human fibroblasts were seeded at 8000 cells/cm2. After
24 h, a line in the monolayer was performed with a ster-
ile p200 pipette tip and medium was changed by alpha-
MEM (control) or alpha-MEM conditioned by MSCs for
24 h. Zero, six, and 12 h after scratching images were
captured under a light microscope (Leica DM2000) with
a digital camera (Leica DFC 295). Image J software
(http://rsbweb.nih.gov/ij/) was used to quantify the
scratch area [27].
Assays were performed in triplicate.
Tube formation assay
Human umbilical vein endothelial cells (HUVECs) were
seeded at 3000 cells/cm2 on 10 mg/mL growth factor-
reduced Matrigel (BD Biosciences, Boston, MA, USA)
and exposed to alpha-MEM (control), alpha-MEM con-
ditioned by MSCs for 24 h or endothelial growth
medium (Lonza, Walkersville, MD, USA) (positive con-
trol) [28]. Five hours later, images were captured under a
light microscope using a digital camera. WimTube pro-
gram (Wimasis GmbH, Munich, Germany) was used to
quantify i) total tube length, ii) total branching point, iii)
total loops.
Assays were performed in triplicate.
T lymphocyte proliferation assay
Canine peripheral blood mononuclear cells were labeled
with carboxyfluorescein succinimidyl ester (Invitrogen/
Molecular Probes, Eugene, OR) and cultivated with
alpha-MEM (control) or alpha-MEM conditioned by
MSCs for 24 h, supplemented with 4 uL (1:10) phyto-
haemaglutinin (Gibco, Invitrogen, Corporation, Scotland,
UK). Five days later, cells were stained with monoclonal
antibody against CD4PE (Serotec, Kidlington, Oxford,
United Kingdom) and analyzed by flow cytometry [29].
Assays were performed in triplicate.
Statistical analysis
Data are presented as mean ± S.E.M. To determine the
statistical significance of intergroup differences a one-
way ANOVA test was used to compare mean values
among all groups and Student’s unpaired t-test or
Mann-Whitney test (non parametric) was used to com-
pare mean values between two groups. p < 0.05 was con-
sidered as statistically significant.
Results
Omental adipose tissue has higher sampling success than
subcutaneous adipose tissue
The age and weight of donor dogs were 10 ± 3 months
and 12 ± 6 Kg (Table 1). Omental samples were pro-
cured from the 14 donors and subcutaneous samples
were procured from 10 of them. Thus, the success sam-
pling rates were 100% (14 of 14) for omental adipose tis-
sue and 71% (10 of 14) for subcutaneous adipose tissue
(Table 1). The average weight of the procured samples
was 5.2 ± 4.5 g for omental and 2.4 ± 3.4 g for subcuta-
neal adipose tissue (Table 1).
Further characterization of adipose-derived MSCs was
performed for samples obtained from the 10 donors in
whom it was possible to obtain both omental and sub-
cutaneous adipose tissues.
Omental adipose tissue and subcutaneous adipose tissue
have MSCs
Cells isolated from both sources adhered to plastic and
showed fibroblast-like morphology (Fig. 1a). Together,
they were negative for hematopoietic markers (CD45
and CD11b) and positive for MSC markers (CD90 and
CD44) (Fig. 1b). When exposed to adipogenic stimulus,
cells differentiated into adipocytes that accumulate lipid
droplets throughout the cytoplasm as confirmed by Oil
Red O staining (Fig. 1c). After 21 days under chondro-
genic induction, sulfated glycosaminoglycans were
present in the matrix as revealed by Safranin O staining
(Fig. 1c). Cell osteogenic differentiation was confirmed
due to the appearance, 3 weeks after exposure to osteo-
genic medium, of calcium deposits that stained with
Alizarin Red (Fig. 1c).
Omental adipose tissue has higher abundance of MSCs
than subcutaneous adipose tissue
The relative abundance of MSCs in omental adipose
tissue was 38 ± 1 CFU-F/g tissue and in subcutane-
ous adipose tissue was 30 ± 1 CFU-F/g tissue,
p < 0.0001 (Fig. 2a-2b).
MSCs derived from omental and subcutaneous adipose
tissues have a similar expansion potential
No statistical difference was observed bewteen
omental- and subcutaneous-derived MSCs regarding
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their proliferation potential up to passage 12 (73 ± 1
vs. 74 ± 1 CDPL) (Fig. 2c). Senescence characteristics
such as cell enlargement, generation of vacuoles and
presence of cellular debris were seen from passage 10
in both MSCs (Fig. 2d).
MSCs derived from omental and subcutaneous adipose
tissues have similar trophic properties
Both adipose-derived MSCs expressed at the same level
the trophic factors bFGF, PDGF and HGF (Fig. 3a). Ac-
cordingly, no differences were observed in their potential
Fig. 1 Omental adipose tissue and subcutaneous adipose tissue have MSCs. a Representative photomicrographs of primary culture of subcutaneous-
and omental-derived cells. b Flow cytometry analysis after immunostaining with monoclonal antibodies against CD45, CD11b, CD90 and CD44 (green
lines) or isotype controls (red lines). c Representative photomicrographs of MSCs stained with Oil Red O (adipogenesis), Safranin O (chondrogenesis) or
Alizarin Red (osteogenesis) 3 weeks after differentiation induction. Control undifferentiated cells are also shown. Abbreviations: SC: subcutaneous
adipose tissue; OM: omental adipose tissue
Table 1 Enrolled animals and procured samples characteristics
Donor (identifier) Age (months) Weight (kilograms) Subcutaneous (grams) Omental (grams)
B001 8 8 not available 6.3
P002 12 15 4.8 8.1
L003 7 11 4.6 9.8
P004 8 12 not available 3.1
K005 12 15 1.9 2.3
L006 7 12 4.5 8.4
P007 8 10 3.2 4.5
C008 12 16 3.1 7.1
C009 11 6 not available 3.2
S010 8 15 5.8 5.9
O011 8 7 not available 3.7
C012 12 10 1.5 3.0
P013 10 6 2.3 4.8
S014 10 18 3.3 3.2
TOTAL 10 ± 3 12 ± 6 2.4 ± 3.4 5.2 ± 4.5
Bahamondes et al. BMC Veterinary Research  (2017) 13:166 Page 4 of 9
to promote human fibroblast proliferation and migration
(Fig. 3b, c and d).
MSCs derived from omental and subcutaneous adipose
tissues have similar vasculogenic properties
Irrespective of their origin, adipose-derived MSCs
expressed VEGF and ANG1 (Fig. 4a). Consequently,
they equally promote tube formation of HUVEC (total
tube length, total branching point and total loops)
(Fig. 4b and c).
MSCs derived from omental and subcutaneous adipose
tissues have similar immunomodulatory properties
The gene expression level of IDO was significantly lower
in omental MSCs than in subcutaneous cells (p < 0.05.
Fig. 5a). The level of IL-10 did not differ significantly be-
tween them. Both adipose-derived MSCs prevent CD4+
T cell-proliferation at the same extent (Fig. 5b).
Discussion
A major challenge associated with MSC-based therapies
is the selection of the source [14]. Here we showed in
young and healthy female dogs that, compared to
subcutaneous adipose tissue, omental adipose tissue is a
more suitable source of MSCs. Since it can be procured
from donors with any body condition, its collection pro-
cedure is always feasible, its cell yield is high and the
MSCs isolated from it have desirable differentiation and
paracrine potentials.
The fact that omental but not subcutaneous adipose
tissue was always procurable may be attributed to vol-
ume variability of fat depots as well as to the expertise
of the professional that procures them. In a study with
1265 dogs, it was shown that the size of collected sam-
ples was determined by the location of the adipose tis-
sue, being visceral samples bigger than subcutaneous
ones [12]. This difference might be critical when donor
should be an emaciated patient due to either a chronic
or a nutritional disease.
We showed that omental adipose tissue yielded a
higher number of viable MSCs per gram of tissue than
subcutaneous adipose tissue. These results are in agree-
ment with other studies showing the same differences in
humans [14] and dogs [10, 15].
Consistent with the results reported for human MSCs,
canine MSCs isolated either from omental or
Fig. 2 Omental adipose tissue has higher abundance of MSCs than subcutaneous adipose tissue. a Quantitative analysis of CFU-Fs per
gram of tissue sampled. b Representative photographs of plates stained with crystal violet 7 days after seeding of nucleated cells from
tissue samples. c Quantitative analysis of CPDL up to passage 12. d Representative photomicrographs of S-MSCs and O-MSCs at passages
1 (P1) and 10 (P10). Abbreviations: SC: subcutaneous adipose tissue; OM: omental adipose tissue; CFU-F/g tissue: colony forming units per
grams of tissue; S-MSCs: mesenchymal stem cells derived from subcutaneous adipose tissue; O-MSCs: mesenchymal stem cells derived
from omental adipose tissue; CDPL: cumulative population doubling level
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subcutaneous adipose tissue followed a lineal trend of
proliferation up to passage 12 and senescence character-
istics appeared at passage 10 [23, 30]. Thus, our data
support a significant but limited expansion potential of
canine MSCs. Hence, the feasibility to be procured and
the cell richness of the sample take higher relevance in
order to choose the best source of canine MSCs.
The secretory activity of MSCs favors a regenerative
microenvironment [31, 32]. The trophic properties of
MSCs depend on the secretion of growth factors that in-
duce cell proliferation and migration [33–35]. We
showed that canine MSCs isolated from omental or sub-
cutaneous tissues express bFGF, PDGF and HGF. Both
bFGF and PDGF elicit target cell proliferation after
ligand-binding induction of receptor oligomerization, ac-
tivation of intrinsic receptor tyrosine kinase and phos-
phorylation of specific residues in the cytoplasmic
region [36–39]. HGF is a pleiotropic factor displaying
mitogenic, motogenic, morphogenetic, and antiapoptotic
activities in different target cells [40]. Indeed, HGF pro-
motes hepatocytes, keratinocytes, renal tubule cell and
endothelial cell proliferation, dissociation of epithelial
cell colonies, cell motility, and invasion through extra-
cellular matrix. More recently, it has been shown that
bFGF, PDGF and HGF can induce biological responses
also on MSCs [41–43]. Our functional studies showed
that, irrespective of the source, canine MSCs secrete ac-
tive mitogenic and motogenic factors.
Fig. 3 MSCs derived from omental and subcutaneous adipose tissues have similar trophic properties. a Quantitative analysis of mRNA levels of
trophic factors. b Quantitative analysis of proliferation kinetic of human fibroblast cultivated with S-MSCs CM or O-MSCs CM evaluated during
12 days. c Representative photomicrographs of invaded area at 0 (T0), six (T6) and 12 (T12) hours post exposure to CMs. d Quantitative analysis of
invaded area evaluated as the percentage of area free of cells at 6 or 12 h post exposure to CM with respect to 0 h. Abbreviations: S-MSCs:
mesenchymal stem cells derived from subcutaneous adipose tissue; O-MSCs: mesenchymal stem cells derived from omental adipose tissue; CM:
conditioned medium; bFGF: basic fibroblast growth factor; PDGF: platelet-derived growth factor; HGF: hepatocyte growth factor
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Vasculogenesis is a crucial step in the wound healing
process [44, 45]. The formation of new blood vessels is
necessary to sustain the newly formed granulation tissue
and the survival of keratinocytes. In this study, we found
that adipose tissue derived MSCs express VEGF and
ANG1. Both stimulate endothelial cell proliferation,
migration, and organization into tubules [46, 47]. Our
functional study showed that MSCs either form omental
or subcutaneous tissue secreted active factors that pro-
mote vasculogenesis.
Since in the functional assays we used human fibro-
blasts or human endothelial cells as target cells, our data
Fig. 4 MSCs derived from omental and subcutaneous adipose tissues have similar vasculogenic properties. a Quantitative analysis of mRNAs levels of
vasculogenic factors. b Representative photomicrographs of tube assay performed with 3D collagen-embedded human umbilical endothelial cells
cultivated 5 h with S-MSCs CM or O-MSCs CM and analyzed by Wimasis software. c Quantitative analysis of total tube length, total branching point
and total loops of tube assay among the different conditions. Abbreviations: S-MSCs: mesenchymal stem cells derived from subcutaneous adipose
tissue; O-MSCs: mesenchymal stem cells derived from omental adipose tissue; CM: conditioned medium; VEGF: vascular endothelial
growth factor; ANG1 angiopoietin 1
Fig. 5 MSCs derived from omental and subcutaneous adipose tissues have similar immunomodulatory properties. a Quantitative analysis of the
mRNAs levels of immunomodulatory factors. Each value was normalized to 18S expression. b Quantitative analysis of total CD4+ T-cells stimulated
and cultivated with S-MSC CM and O-MSC CM after 5 days. Abbreviations: S-MSCs: mesenchymal stem cells derived from subcutaneous adipose
tissue; O-MSCs: mesenchymal stem cells derived from omental adipose tissue; CM: conditioned medium; IDO indoleamine-pyrrole 2,3-dioxygenase;
IL-10 interleukin 10
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prove than trophic and vasculogenic factors secreted by
MSCs isolated from dog omental or subcutaneous adi-
pose tissue overcome species-specificity barrier. In order
to further characterize the products secreted by canine
MSCs it would be relevant to perform the functional ex-
periments using target cells from dogs and other species.
Much attention has been paid to the immunomodula-
tory properties of MSCs. Several studies have shown a
paracrine suppressive effect on T cells, B cells, mono-
cytes and macrophages [48–50]. We showed similar
gene expression levels of IL-10 in MSCs from both
sources studied. Though, the expression of IDO in
MSCs derived from subcutaneous adipose tissue was 11-
fold higher than in MSCs derived from omentum. IDO
catalyzes the conversion of tryptophan to kynurenine
and inhibits T cell proliferation due to tryptophan deple-
tion [51]. Nevertheless, this is not the unique mechan-
ism supporting the immunosuppresive potential of
MSCs [52–55]. That should explain why, despite of the
differences observed in IDO mRNA levels, in the func-
tional assay MSCs from both sources inhibit at the same
magnitude CD4+ T cell proliferation. Our results appear
consistent with previous findings for human and canine
MSCs [4, 56, 57].
Data here presented not only shall be useful for evi-
dence based-selection of MSC source but also to expand
the frontiers of the use of canine MSCs as they prove to
produce active trophic, vasculogenic and immunomodu-
lator soluble factors.
Conclusion
Compared to subcutaneous adipose tissue, omental adi-
pose tissue is a more suitable source of MSCs in dogs.
Since it can be procured from donors with any body
condition, its collection procedure is always feasible, its
cell yield is high and the MSCs isolated from it have de-
sirable differentiation and paracrine potentials.
Additional file
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